<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>334</serviceExecutionTime><Drug id="68734"><DrugName>smallpox DNA vaccine (SynCon/electroporation), Inovio Pharmaceuticals</DrugName><DrugSynonyms><Name><Value>smallpox DNA vaccine (SynCon/electroporation), Inovio Pharmaceuticals</Value></Name></DrugSynonyms><CompanyOriginator id="22403">Inovio Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="22403">Inovio Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="68734" type="Drug"><TargetEntity id="661133" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="22403" type="Company"><TargetEntity id="4295901003" type="organizationId">Inovio Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1270" type="ciIndication"><TargetEntity id="B03" type="ICD10"/><TargetEntity id="050.9" type="ICD9"/><TargetEntity id="10041197" type="MEDDRA"/><TargetEntity id="D012899" type="MeSH"/><TargetEntity id="-1532547108" type="omicsDisease"/><TargetEntity id="868" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="1270">Variola virus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="12378">Prophylactic vaccine</Action><Action id="1879">DNA vaccine</Action></ActionsSecondary><Technologies><Technology id="611">Dermatological formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2013-09-27T05:13:40.000Z</LastModificationDate><ChangeDateLast>2013-09-27T00:00:00.000Z</ChangeDateLast><AddedDate>2010-10-27T09:26:14.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="22403"&gt;Inovio Pharmaceuticals&lt;/ulink&gt; was investigating a synthetic consensus (SynCon) multivalent DNA vaccine combining eight  DNA plasmids, delivered using its using  skin electroporation delivery device, for the potential prevention of smallpox virus infection [&lt;ulink linkType="Reference" linkID="1142326"&gt;1142326&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1141724"&gt;1141724&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1154268"&gt;1154268&lt;/ulink&gt;].  In October 2010,  research was ongoing [&lt;ulink linkType="Reference" linkID="1141724"&gt;1141724&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In January 2011, results showed non-human primates vaccinated with intradermal electroporation achieved a stronger antibody response and protection against a virus challenge compared with im electroporation and responses were comparable to those produced by a stock piled Dryvax smallpox vaccine [&lt;ulink linkType="Reference" linkID="1163631"&gt;1163631&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2010, data were reported demonstrating that  the  vaccine protected animals in smallpox challenge models, including   non-human primate models, by eliciting potent neutralizing antibody responses when delivered using  skin electroporation delivery device [&lt;ulink linkType="Reference" linkID="1139430"&gt;1139430&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1141724"&gt;1141724&lt;/ulink&gt;]. In December 2010, similar data were published [&lt;ulink linkType="Reference" linkID="1154268"&gt;1154268&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22403">Inovio Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1270">Variola virus infection</Indication><StatusDate>2013-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22403">Inovio Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1270">Variola virus infection</Indication><StatusDate>2010-01-27T00:00:00.000Z</StatusDate><Source id="1142326" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22403">Inovio Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="133218" title="Defense threat reduction agency to award Inovio with grant for smallpox vaccine"/></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="9038"><DrugName>MSI-733</DrugName><DrugSynonyms><Name><Value>MSI-733</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17924">Genaera Corp</CompanyOriginator><CompaniesSecondary><Company id="17924">Genaera Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9038" type="Drug"><TargetEntity id="220681" type="siDrug">MSI-733</TargetEntity></SourceEntity><SourceEntity id="17924" type="Company"><TargetEntity id="4295907055" type="organizationId">Genaera Corp</TargetEntity></SourceEntity><SourceEntity id="129" type="ciIndication"><TargetEntity id="10017944" type="MEDDRA"/><TargetEntity id="D005767" type="MeSH"/><TargetEntity id="-728854171" type="omicsDisease"/><TargetEntity id="369" type="siCondition"/></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"/><TargetEntity id="D007239" type="MeSH"/><TargetEntity id="-367065996" type="omicsDisease"/><TargetEntity id="799" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="129">Gastrointestinal disease</Indication><Indication id="746">Infectious disease</Indication></IndicationsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2001-02-09T19:20:02.000Z</LastModificationDate><ChangeDateLast>2001-02-09T19:20:02.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="9038"&gt;MSI-733&lt;/ulink&gt; was being investigated by Magainin as a tablet formulation for the potential treatment of gastrointestinal infections [&lt;ulink linkType="reference" linkID="191231"&gt;191231&lt;/ulink&gt;]. It showed little or no systemic absorption in animal studies [&lt;ulink linkType="reference" linkID="173293"&gt;173293&lt;/ulink&gt;], but no development has been reported since 1994 [&lt;ulink linkType="reference" linkID="169388"&gt;169388&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17924">Genaera Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate>2001-02-09T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17924">Genaera Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="129">Gastrointestinal disease</Indication><StatusDate>2001-02-09T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17924">Genaera Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="129">Gastrointestinal disease</Indication><StatusDate>1993-04-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17924">Genaera Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="746">Infectious disease</Indication><StatusDate>1993-04-01T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>